Humza Ilyas, MD
MOHS-Micrographic Surgery · Atlanta, GANPI 1417120601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 26.3% of the total. That places this record below the midpoint for mohs-micrographic surgery clinicians in GA, where the typical reported total is $3,443.
Across 139 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$790
- LEO Pharma Inc.$433
- Novartis$186
- Incyte Corporation$174
- Johnson & Johnson$163
- Lilly USA, LLC$136
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,007100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $790 |
| LEO Pharma Inc. | 17 | $433 |
| Novartis | 7 | $186 |
| Incyte Corporation | 8 | $174 |
| Johnson & Johnson | 8 | $163 |
| Lilly USA, LLC | 7 | $136 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| Organogenesis Inc. | 5 | $100 |
| Dermavant Sciences, Inc. | 5 | $99 |
| Hydrofera LLC | 2 | $98 |
| Sun Pharmaceutical Industries Inc. | 5 | $94 |
| UCB, Inc. | 4 | $73 |
| Biofrontera Inc. | 4 | $70 |
| Mayne Pharma Commercial LLC | 4 | $68 |
| Amgen | 3 | $66 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $53 |
| Galderma Laboratories, L.p. | 3 | $51 |
| Boehringer Ingelheim | 2 | $43 |
| Pfizer | 2 | $37 |
| Sanofi | 1 | $33 |
| Verrica Pharmaceuticals Inc. | 1 | $21 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| LNHC, Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$3,007 in reported general payments places this provider in the 40th percentile of 40 mohs-micrographic surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 152 | $1,478 |
| Cephalexin | 245 | $1,260 |
| Mupirocin | 94 | $643 |
| Tramadol Hcl | 69 | $180 |
| Triamcinolone Acetonide | 15 | $131 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $70 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Atlanta
- David OlanskyAtlanta$13K
- Diamondis PapadopoulosAtlanta$9K
- Melissa BabcockAtlanta$3K
- Julia NeckmanAtlanta$3K
- Valerie TruongAtlanta$2K
- Mary Alice MinaAtlanta$533
- Amy KimAtlanta$430
- Mark BaucomAtlanta$146
- Wallace NozileStockbridge$213K
- Brandon BurrowayDuluth$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.